The Current Landscape of Glioblastoma Biomarkers in Body Fluids
Cancers · 26.07.2023 · 15 (15) · 3804
DOI: 10.3390/cancers15153804 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.07.2023. Verfasst von Saba Zanganeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC 2759…. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM) is a highly aggressive and lethal primary brain cancer that necessitates early detection and accurate diagnosis for effective treatment and improved patient outcomes. Traditional diagnostic methods, such as imaging techniques and tissue biopsies, have limitations in providing real-time information and distinguishing treatment-related changes from tumor progression. Liquid biopsies, used to analyze biomarkers in body fluids, offer a non-invasive and dynamic approach to detecting and monitoring GBM. This article provides an overview of GBM biomarkers in body fluids, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), cell-free RNA (cfRNA), microRNA (miRNA), and extracellular vesicles. It explores the clinical utility of these biomarkers for GBM detection, monitoring, and prognosis. Challenges and limitations in implementing liquid biopsy strategies in clinical practice are also discussed. The article highlights the potential of liquid biopsies as valuable tools for personalized GBM management but underscores the need for standardized protocols and further research to optimize their clinical utility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran 15719-14911, Iran.
- Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz 71348-14336, Iran.
- Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
ORCID-Profile: Saba Zanganeh, Elham Abbasgholinejad, Mohammad Doroudian, Soumya Rahima Benhabbour
Zitieren
APA
Zanganeh, S., Abbasgholinejad, E., Doroudian, M., Esmaelizad, N., Farjadian, F., & Benhabbour, S. R. (2023). The Current Landscape of Glioblastoma Biomarkers in Body Fluids. Cancers, 15(15), 3804. https://doi.org/10.3390/cancers15153804
Vancouver
Zanganeh S, Abbasgholinejad E, Doroudian M, Esmaelizad N, Farjadian F, Benhabbour SR. The Current Landscape of Glioblastoma Biomarkers in Body Fluids. Cancers. 2023;15(15):3804. doi:10.3390/cancers15153804
BibTeX
@article{Zanganeh2023,
author = {Zanganeh, Saba and Abbasgholinejad, Elham and Doroudian, Mohammad and Esmaelizad, Nazanin and Farjadian, Fatemeh and Benhabbour, Soumya Rahima},
title = {The Current Landscape of Glioblastoma Biomarkers in Body Fluids},
journal = {Cancers},
year = {2023},
volume = {15},
number = {15},
pages = {3804},
doi = {10.3390/cancers15153804}
}
EUVIMED